Osteosarcoma - Pipeline Review (H2 2018) Featuring Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Merck, Pfizer, and more - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Osteosarcoma - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. Osteosarcoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 22, 8, 1, 23 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 2 and 4 molecules, respectively. Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Advenchen Laboratories LLCAmgen IncAntiCancer IncArrowhead Pharmaceuticals IncAutolus Therapeutics PlcAVEO Pharmaceuticals IncBayer AGBellicum Pharmaceuticals IncBoehringer Ingelheim GmbHBristol-Myers Squibb CoCellectar Biosciences IncCellestia Biotech AGCellmid LtdCorMedix IncEisai Co LtdEndocyte IncExelixis IncIntezyne IncIpsen SAIsofol Medical ABJiangsu Hengrui Medicine Co LtdMacroGenics IncMateon Therapeutics IncMD Biosciences GmbHMerck & Co IncMerck KGaANektar TherapeuticsNovartis AGOncolys BioPharma IncOno Pharmaceutical Co LtdPfizer IncSorrento Therapeutics IncTeijin Pharma LtdTyme Technologies Incand more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/h2d3t6/osteosarcoma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005307/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 06:04 AM/DISC: 09/19/2018 06:04 AM


Update hourly